DLDanilo Vieira de Lara

Danilo Vieira de Lara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Danilo Vieira de Lara has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacogenetic Testing-Guided Treatment for Oncology: An Overview of Reviews

    by Danilo Vieira de Lara, Daniela Oliveira de Melo, Daniele Y Kawakami, Thuane S Gonçalves, Paulo Cjl Santos

    Pharmacogenetics is the relationship between an individual’s genetic variations and their response to pharmacological treatment. We conducted an overview of reviews on the use of post-treatment pha...


  • Pharmacogenetics of Clopidogrel and Warfarin in the Treatment of Cardiovascular Diseases: An Overview of Reviews

    by Danilo Vieira de Lara, Daniela Oliveira de Melo, Lucas Caetano Araújo Silva, Thuane Sales Gonçalves, Paulo Caleb Júnior Lima Santos

    Pharmacogenetics (PGx) is the relationship between an individual's genetic variations and the response to pharmacological treatment. We chose to perform an overview of reviews on PGx testing-guided...


  • Pharmacogenetic Testing in Psychiatry and Neurology: an Overview of Reviews

    by Danilo Vieira de Lara, Daniela Oliveira de Melo, Rafael Augusto Mantovani Silva, Paulo Caleb Junior Lima de Santos

    Pharmacogenetic testing is available to healthcare professionals to guide drug selection and prevent adverse events. However, its implementation in the clinical practice of psychiatry/neurology sti...


  • Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics

    by Miriam Saiz-Rodríguez, Dolores Ochoa, Carmen Belmonte, Manuel Román, Danilo Vieira de Lara, Pablo Zubiaur, Dora Koller, Gina Mejía, Francisco Abad-Santos

    Agomelatine is an agonist of the melatoninergic receptors used for the treatment of depression. Our aim was to evaluate the effect of genetic polymorphisms in metabolising enzymes and the P-glycoprotein transporter on agomelatine pharmacokinetics and pharmacodynamics. Twenty-eight healthy volunteers receiving a single 25 mg oral dose of agomelatine, were genotyped for nine polymorphisms in cytochrome P450 enzymes (CYP1A2, CYP2C9 and CYP2C19) and adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1), by real-time polymerase chain reaction . Agomelatine concentrations were measured by high performance liquid chromatography coupled to a tandem mass spectrometry detector. We calculated a CYP1A2 activity score that was directly correlated with agomelatine pharmacokinetics. Individuals with a decreased enzyme activity (*1C carriers) had a lower clearance and accumulated higher concentrations of agomelatine. In contrast, individuals with a high CYP1A2 inducibility (*1F or *1B carriers) showed an extensive clearance and lower agomelatine concentrations. The apparently marked differences between races were due to the different CYP1A2 genotype distribution. CYP2C9 intermediate/poor metabolisers showed a higher area under the concentration-time curve and maximum concentration. ABCB1 G2677T/A polymorphism affected the time to reach maximum concentration, as subjects carrying A/A+A/T genotypes showed higher values. No association was found for CYP2C19 phenotype. Agomelatine did not produce any change in blood pressure, heart rate or QT interval. CYP1A2 polymorphisms affect agomelatine pharmacokinetics. CYP1A2 phenotype inferred from the genotyping of CYP1A2*1C, *1F and *1B alleles might be a potential predictor of agomelatine exposure. ABCB1 G2677T/A could affect agomelatine absorption, as subjects with A/A+A/T genotypes had lower agomelatine concentration and they take more time to reach the maximum concentration.


  • Open Access

    Effects of Hypericum perforatum on turning behavior in an animal model of Parkinson's disease

    by Débora Dalla Vecchia, Marissa Giovanna Schamne, Marcelo Machado Ferro, Ana Flávia Chaves dos Santos, Camila Lupepsa Latyki, Danilo Vieira de Lara, Juliana Ben, Eduardo Luiz Moreira, Rui Daniel Prediger, Edmar Miyoshi

    Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by the slow and progressive death of dopaminergic neurons in the (substantia nigra pars compact). Hypericum perforatum (H. perforatum) is a plant widely used as an antidepressant, that also presents antioxidant and anti-inflammatory properties. We evaluated the effects of H. perforatum on the turning behavior of rats submitted to a unilateral administration of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle as an animal model of PD. The animals were treated with H. perforatum (100, 200, or 400 mg/kg, v.o.) for 35 consecutive days (from the 28th day before surgery to the 7th day after). The turning behavior was evaluated at 7, 14 and 21 days after the surgery, and the turnings were counted as contralateral or ipsilateral to the lesion side. All tested doses significantly reduced the number of contralateral turns in all days of evaluation, suggesting a neuroprotective effect. However, they were not able to prevent the 6-OHDA-induced decrease of tyrosine hydroxylase expression in the lesioned striatum. We propose that H. perforatum may counteract the overexpression of dopamine receptors on the lesioned striatum as a possible mechanism for this effect. The present findings provide new evidence that H. perforatum may represent a promising therapeutic tool for PD.